PetIQ, Inc operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers Rx pet medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; and OTC medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars.
Read More…
Industry, Sector and Symbol
Industry Drugs, proprietaries, & sundries
Sub-IndustryN/A
SectorMedical
Phone208-939-8900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$528.61 million
Profitability
Miscellaneous
Employees1,452
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
PetIQ (NASDAQ:PETQ) Frequently Asked Questions
What is PetIQ's stock symbol?
PetIQ trades on the NASDAQ under the ticker symbol "PETQ."
How were PetIQ's earnings last quarter?
PetIQ Inc (NASDAQ:PETQ) posted its quarterly earnings data on Wednesday, August, 7th. The company reported $0.70 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.35 by $0.35. The firm earned $220.60 million during the quarter, compared to the consensus estimate of $193.89 million. PetIQ had a return on equity of 10.17% and a net margin of 0.68%. The firm's revenue was up 28.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.66 EPS. View PetIQ's Earnings History.
When is PetIQ's next earnings date?
What guidance has PetIQ issued on next quarter's earnings?
PetIQ updated its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $680-680 million, compared to the consensus revenue estimate of $610.98 million.
What price target have analysts set for PETQ?
5 analysts have issued twelve-month price objectives for PetIQ's stock. Their predictions range from $35.00 to $50.00. On average, they anticipate PetIQ's stock price to reach $42.40 in the next twelve months. This suggests a possible upside of 55.7% from the stock's current price. View Analyst Price Targets for PetIQ.
What is the consensus analysts' recommendation for PetIQ?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PetIQ in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PetIQ.
What are Wall Street analysts saying about PetIQ stock?
Here are some recent quotes from research analysts about PetIQ stock:
- 1. According to Zacks Investment Research, "PetIQ, Inc. is a pet medication and wellness company. Its product consists of Rx Medications, OTC Medications and Supplies, Health and Wellness Products. The Company serves retail stores across the mass, club, grocery, pharmacy and e-commerce channels. PetIQ, Inc. is based in Eagle, United States. " (8/9/2019)
- 2. Jefferies Financial Group Inc analysts commented, "PETQ remains our top small-cap growth idea post our mgmt meetings / co.’s bullish presentation at the ICR conf. in Orlando, FL. Mgmt underscored secular tailwinds in the attractive pet health industry remain very much in place, the co." (1/15/2019)
Has PetIQ been receiving favorable news coverage?
Media stories about PETQ stock have been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PetIQ earned a news impact score of -1.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for PetIQ.
Who are some of PetIQ's key competitors?
What other stocks do shareholders of PetIQ own?
Who are PetIQ's key executives?
PetIQ's management team includes the folowing people:
- Mr. McCord Christensen, Chairman & CEO (Age 47)
- Ms. Susan Sholtis, Pres (Age 53)
- Mr. John Newland, Chief Financial Officer (Age 55)
- Mr. Robert Michael Herrman, Gen. Counsel & Sec.
- Mr. Adam Fellers, Sr. VP of Sales
When did PetIQ IPO?
(PETQ) raised $86 million in an initial public offering (IPO) on Friday, July 21st 2017. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies and William Blair acted as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.
Who are PetIQ's major shareholders?
PetIQ's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Waddell & Reed Financial Inc. (6.32%), BlackRock Inc. (5.48%), TimesSquare Capital Management LLC (4.22%), Wasatch Advisors Inc. (4.01%), State of New Jersey Common Pension Fund D (3.87%) and Janus Henderson Group PLC (3.45%). Company insiders that own PetIQ stock include Ecp Helios Partners Iv, LP, James Nathan Clarke, John Newland, Mccord Christensen, Ronald Kennedy, Susan Sholtis and Will Santana. View Institutional Ownership Trends for PetIQ.
Which major investors are selling PetIQ stock?
PETQ stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Renaissance Technologies LLC, Bank of America Corp DE, TimesSquare Capital Management LLC, Argent Capital Management LLC, Landscape Capital Management L.L.C., Chartwell Investment Partners LLC and Nepsis Inc.. Company insiders that have sold PetIQ company stock in the last year include Ecp Helios Partners Iv, LP, James Nathan Clarke, John Newland, Mccord Christensen, Susan Sholtis and Will Santana. View Insider Buying and Selling for PetIQ.
Which major investors are buying PetIQ stock?
PETQ stock was acquired by a variety of institutional investors in the last quarter, including Intrinsic Edge Capital Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Waddell & Reed Financial Inc., Calamos Advisors LLC, BlackRock Inc., Vanguard Group Inc. and Nuveen Asset Management LLC. Company insiders that have bought PetIQ stock in the last two years include James Nathan Clarke and Ronald Kennedy. View Insider Buying and Selling for PetIQ.
How do I buy shares of PetIQ?
Shares of PETQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is PetIQ's stock price today?
One share of PETQ stock can currently be purchased for approximately $27.23.
How big of a company is PetIQ?
PetIQ has a market capitalization of $768.43 million and generates $528.61 million in revenue each year. The company earns $-780,000.00 in net income (profit) each year or $1.25 on an earnings per share basis. PetIQ employs 1,452 workers across the globe.View Additional Information About PetIQ.
What is PetIQ's official website?
How can I contact PetIQ?
PetIQ's mailing address is 923 S. Bridgeway Pl., EAGLE ID, 83616. The company can be reached via phone at 208-939-8900 or via email at [email protected]
MarketBeat Community Rating for PetIQ (NASDAQ PETQ)
MarketBeat's community ratings are surveys of what our community members think about PetIQ and other stocks. Vote "Outperform" if you believe PETQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
